Clinical Trial Detail

NCT ID NCT01871675
Title Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

non-Hodgkin lymphoma

Therapies

Rituximab

Duvelisib

Bendamustine

Age Groups: adult

No variant requirements are available.